Business Wire

Historic Partnership between the Weizmann Institute of Science and Institut Curie

25.3.2019 19:54:00 EET | Business Wire | Press release

Share

On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics.

Collaborative research programs

This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot. Each research program will be organized around a pair of researchers with a scientist from Institut Curie and a scientist from the Weizmann Institute of Sciences, who will receive support on the annual basis. This partnership also includes exchanges of scientists and a Curie-Weizmann symposium organized every two years, with alternate locations in Rehovot, Israel, and in Paris, which will be focused on one of the subjects of research cooperation.
To finance the start of this cooperation, Institut Curie and the Weizmann Institute of Sciences will finance this research program for €200,000 each, and will organize a joint fundraiser with philanthropists and corporate sponsors.

Projects with high hopes
There are numerous common interests between the two Institutes. They can range from the description of defects in cell nuclei to the mechanics of cell migration, or the behavior of neural networks. A few examples of exciting ongoing projects are highlighted below.
During his sabbatical visit at Institut Curie in 2012, Professor Nir Gov (Weizmann Institute) participated in several projects ranging from cell migration to collective cell behaviors and neuron growth. For instance, he developed a theory in collaboration with Raphael Voituriez (Sorbonne University), which explains the observations of the team of Matthieu Piel (Institut Curie) on the links between persistence and speed of migrating cells. This theory gave rise to collaborative developments between these three teams to predict important aspects of the migratory behavior of immune cells.
He also collaborated with Pascal Silberzan at Institut Curie to understand the behavior of cells packed at very high density on a surface. This joint work combining experiments and theory, has highlighted the importance of an intrinsic biological ageing of the cell population. This project has helped understanding how cells can come to an arrest while maintaining a capacity to respond to external perturbations such as an injury.
Elisha Moses (Weizmann Institute) has a longstanding interaction with the group of Professor Jean-Louis Viovy (Institut Curie), now headed by Stéphanie Descroix, on the applications of microfluidic devices to the study of living neuronal networks. He spent three months in Paris, during which he and Dr. Catherine Villard of the Descroix lab developed an optogenetic assay for guiding axonal growth. This work has the potential for controlling growth of neurons and of neuronal tumors within the brain. Drs. M. Vignes and R. Renault, two talented researchers who were working on the project as students, have now graduated and branched off into very interesting conceptual and practical applications of this approach.

An important complementarity
The two institutions are both highly complementary and display many mutually common attributes.
Institut Curie is the premier research center in France conducting cancer research, including all facets of carcinogenesis. Its research center brings together 1,200 researchers working in 12 joint research units organized in four areas based on natural scientific interactions and robust medical potentiality. A strong advocate of international cooperation , it welcomes more than 80 nationalities. Equipped with advanced technology platforms, it is an important resource for researchers around the world. Institut Curie is also a state-of-the-art hospital complex that provides care and support for all cancer types and welcomes more than 50,000 patients each year. It has developed particularly innovative treatments directly from the work of its research center. Institut Curie also trains students in science and cancer research with the goal of increasing the knowledge about the topic.
The Weizmann Institute of Science is among the ten premier institutes of fundamental research in the world: 2,500 scientists work on its campus in Rehovot in the complementary fields of mathematics and computer science, physics, biology, chemistry, and biochemistry. The Weizmann Institute of Science has a long history of research and discoveries rooted in a mission of advancement of science for the benefit of humanity; cancer research accounts for 40% of the total budget of the Institute, which shapes and hosts a large part of the leadership in Israel and contributes to the advancement and understanding of scientific issues among all audiences.
Both institutions have powerful means of technology transfer that leverage the discoveries of their labs for the benefit of patients, whether through the creation of medications, medical devices or other technologies.

A shared vision of science
Science at the service of people - this is the best way to describe the credo of the two institutes, both of which were founded upon great personalities who have made an important mark in the history of the world.
Chaim Weizmann, chemist and author of many discoveries and publications, is the founder of the Weizmann Institute, and was the first president of the State of Israel between 1949 and 1952. Marie Curie, born Maria Sklodowska, founded the Radium Institute in 1909. The first female professor and holder of a chair position at the Sorbonne, the first woman to win two Nobel prizes and be enshrined at the Pantheon in Paris on her own merit. In many ways, these two scientists have had a remarkable journey.
But beyond these prestigious founders, the two institutes share the same vision of science, at the service of people and driven by strong values, the same curiosity for discovery and knowledge at the service of human health.
The Weizmann Institute of Science and Institut Curie also share a common belief that international collaborations in the field of institut-curie.org science and the exchange of ideas across interdisciplinary boundaries can accelerate progress to the benefit of humanity.
It is this common ground which today enables this collaboration to take root and which will tomorrow allow us to multiply efforts and as a result enjoy major new discoveries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Yohan Philippe
yohan.philippe@curie.fr
+33 (0)1 56 24 55 53

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 20264.5.2026 21:25:00 EEST | Press release

Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at the EWMA‑DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504487743/en/ MariCell® Solid This year, The European Wound Management Association's (EWMA) meeting is held in conjunction with the Deutscher Wundkongress (DEWU); combining two major wound-care congresses into a single forum for scientific exchange, education, and clinical discussion. At this year’s conference, Kerecis will highlight growing clinical experience with intact fish‑skin grafts across a broad range of wound indications, supported by two Kerecis‑led scientific symposia, multiple oral and poster presentations, and direct engagement with clinicians at Booth D30, located adjacent

Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit4.5.2026 21:00:00 EEST | Press release

CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today officially announces the launch of its North American subsidiary, CTIBIOTECH USA™. The official launch took place today at the prestigious SelectUSA Investment Summit in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504107996/en/ From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine Operating from its new United States base in the thriving life sciences “Cellicon Valley” hub of Philadelphia, Pennsylvania, in association with BioLabs for Advanced Therapeutics, CTIBIOTECH USA™ will provide the company's proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. By producing and supplying these cutting-edge human bioassays domesti

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 17:28:00 EEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 16:00:00 EEST | Press release

Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading transformative and meaningful customer experiences. These leading organizations are turning everyday interactions into seamless, cross-channel journeys that deliver meaningful business impact and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye